advertising
-
1
Kurup SK, Levy-Clarke G, Calvo KR, et al: Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids. .Clin Exp Ophthalmol 35::468. ,2007. .
-
2
Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes: Non-Hodgkin’s Lymphoma Classification Project. .J Clin Oncol 16::2780. ,1998. .
-
3
Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. .Blood 84::1361. ,1994. .
-
4
Li L: Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information. .Bioinformatics 22::466. ,2006. .
-
5
Cheson BD, Portlock C, Vose JM: Diffuse large B-cell lymphoma. Lymphoma Research Foundation. Available at: http://www.lymphoma.org/atf/cf/%7B0363CDD6-51B5-427B-BE48-E6AF871ACEC9%7D/DIFFUSE%20LARGE%20B-CELL.PDF. Accessed October 15. ,2008. .
-
6
DeFronzo D, Saffran B: A unique presentation of non-Hodgkin’s lymphoma in the foot. .J Foot Surg 31::112. ,1992. .
-
7
Gratzinger D, Zhao S, Marinelli RJ, et al: Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. .Am J Pathol 170::1362. ,2007. .
-
8
Kallab AM: Diffuse large cell lymphoma. June 30, 2006. Available at: http://www.emedicine.com/med/topic1360.htm. Accessed October 7. ,2008. .
-
9
Lenz G, Nagel I, Siebert R, et al: Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma. .J Exp Med 204::633. ,2007. .
-
10
Bea S, Zettl A, Wright G, et al: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression–based survival prediction. .Blood 106::3183. ,2005. .
-
11
Armitage JO: How I treat patients with diffuse large B-cell lymphoma. .Blood 110::29. ,2007. .
-
12
Sáez AI, Sáez AJ, Artiga MJ, et al: Building an outcome predictor model for diffuse large B-cell lymphoma. .Am J Pathol 164::613. ,2004. .
-
13
Adida C, Haioun C, Gaulard P, et al: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. .Blood 96::1921. ,2000. .
-
14
Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual, 6th Ed, Springer, New York. ,2002. .
-
15
Groves FD, Linet MS, Travis LB, et al: Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. .J Natl Cancer Inst 92::1240. ,2000. .
-
16
Winter JN, Weller EA, Horning SJ, et al: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. .Blood 107::4207. ,2006. .
-
17
[No authors listed]: A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. .N Engl J Med 329::987. ,1993. .
-
18
Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. .J Clin Oncol 24::3121. ,2006. .
-
19
Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. .J Clin Oncol 17::268. ,1999. .
-
20
Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma: Groupe d’Etude des Lymphomes de l’Adulte (GELA). .Blood 87::265. ,1996. .
-
21
Iqbal J, Neppalli VT, Wright G, et al: BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. .J Clin Oncol 24::961. ,2006. .
-
22
Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). .Blood 101::4279. ,2003. .
-
23
Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). .Blood 102::29a. ,2003. .
-
24
Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. .J Clin Oncol 23::4117. ,2005. .
Diffuse Large B-Cell Lymphoma of the Ankle
A Case Study of Surgical Intervention and Outcome
Search for other papers by Mark J. Mendeszoon in
Current site
Google Scholar
PubMed
Search for other papers by Kyle R. Wire in
Current site
Google Scholar
PubMed
The most common type of non-Hodgkin’s lymphoma is the B-cell type. We report herein a type of B-cell lymphoma in an adult ankle. A 63-year-old woman presented with a painful growth on the anteromedial aspect of her right ankle that was later diagnosed as a form of non-Hodgkin’s lymphoma. Clinically, the single mass appeared bluish in color, painful on palpation, and warm to the touch. The overlying skin was friable, and the lesion did not transilluminate. Histopathologic examination revealed a diffuse large B-cell lymphoma of germinal center origin on surgical excision. This case report focuses on the clinical presentation, surgical intervention, and overall outcome of a rare case of lymphoma of the ankle. (J Am Podiatr Med Assoc 100(6): 505–510, 2010)
advertising
